索磷布韦和达卡他韦抗病毒治疗未能清除戊型肝炎病毒血症并恢复戊型肝炎病毒/丙型肝炎病毒合并感染的肝移植受者体内的反应性T细胞。 - Suppr

Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient.

作者信息

Donnelly Mhairi C, Imlach Stuart N, Abravanel Florence, Ramalingam Sandeep, Johannessen Ingolfur, Petrik Juraj, Fraser Alistair R, Campbell John D M, Bramley Peter, Dalton Harry R, Hayes Peter C, Kamar Nassim, Simpson Kenneth J

机构信息

Department of Hepatology and Scottish Liver Transplant Unit, Royal Infirmary of Edinburgh, Edinburgh, UK.

Microbiology and Components Group, Scottish National Blood Transfusion Service Research, Development and Innovation, Edinburgh, UK.

出版信息

Gastroenterology. 2017 Jan;152(1):300-301. doi: 10.1053/j.gastro.2016.05.060. Epub 2016 Nov 21.

DOI:10.1053/j.gastro.2016.05.060

PMID:27883881

Abstract

摘要

相似文献

Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient.

Gastroenterology. 2017 Jan;152(1):300-301. doi: 10.1053/j.gastro.2016.05.060. Epub 2016 Nov 21.

UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jan 15;1073:183-190. doi: 10.1016/j.jchromb.2017.12.018. Epub 2017 Dec 12.

Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.

Aliment Pharmacol Ther. 2016 Jun;43(12):1319-29. doi: 10.1111/apt.13629. Epub 2016 Apr 21.

Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.

AIDS. 2016 Jan 2;30(1):93-8. doi: 10.1097/QAD.0000000000000887.

Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.

Int J Infect Dis. 2016 Aug;49:151-3. doi: 10.1016/j.ijid.2016.06.020. Epub 2016 Jul 1.

Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.

Clin Ther. 2016 Feb;38(2):404-12. doi: 10.1016/j.clinthera.2015.12.017. Epub 2016 Feb 3.

Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in an HIV-HCV-coinfected patient.

Antivir Ther. 2015;20(3):353-6. doi: 10.3851/IMP2841. Epub 2014 Aug 8.

A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.

Exp Clin Transplant. 2018 Feb;16(1):61-67. doi: 10.6002/ect.2016.0296. Epub 2017 Nov 15.

Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.

BMC Infect Dis. 2017 Mar 1;17(1):182. doi: 10.1186/s12879-017-2287-y.

Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation: Results From the ANRS CO23 CUPILT Study.

Transplantation. 2018 Jan;102(1):119-126. doi: 10.1097/TP.0000000000001928.

引用本文的文献

Viral hepatitis E: Clinical manifestations, treatment, and prevention.

Liver Res. 2024 Jan 6;8(1):11-21. doi: 10.1016/j.livres.2024.01.001. eCollection 2024 Mar.

Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment.

JHEP Rep. 2024 Jan 3;6(3):100989. doi: 10.1016/j.jhepr.2023.100989. eCollection 2024 Mar.

Hepatitis E infection: A review.

World J Virol. 2023 Dec 25;12(5):262-271. doi: 10.5501/wjv.v12.i5.262.

Treatment of Hepatitis E.

Adv Exp Med Biol. 2023;1417:215-226. doi: 10.1007/978-981-99-1304-6_15.

Repurposing of artesunate, an antimalarial drug, as a potential inhibitor of hepatitis E virus.

Arch Virol. 2023 Apr 28;168(5):147. doi: 10.1007/s00705-023-05770-1.

Sofosbuvir in the Treatment of Hepatitis E virus Infection: A Review of and Evidence.

J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1225-1237. doi: 10.1016/j.jceh.2022.02.003. Epub 2022 Feb 22.

World J Gastroenterol. 2022 Mar 28;28(12):1226-1238. doi: 10.3748/wjg.v28.i12.1226.

Viral Interference of Hepatitis C and E Virus Replication in Novel Experimental Co-Infection Systems.

Cells. 2022 Mar 8;11(6):927. doi: 10.3390/cells11060927.

Viral hepatitis in 2021: The challenges remaining and how we should tackle them.

World J Gastroenterol. 2022 Jan 7;28(1):76-95. doi: 10.3748/wjg.v28.i1.76.

Treatment for chronic hepatitis E virus infection: A systematic review and meta-analysis.

J Viral Hepat. 2021 Mar;28(3):454-463. doi: 10.1111/jvh.13456. Epub 2020 Dec 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient.

作者信息

机构信息

Department of Hepatology and Scottish Liver Transplant Unit, Royal Infirmary of Edinburgh, Edinburgh, UK.

Microbiology and Components Group, Scottish National Blood Transfusion Service Research, Development and Innovation, Edinburgh, UK.

出版信息

Gastroenterology. 2017 Jan;152(1):300-301. doi: 10.1053/j.gastro.2016.05.060. Epub 2016 Nov 21.

DOI:10.1053/j.gastro.2016.05.060

PMID:27883881

Abstract

摘要

相似文献

Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient.

Gastroenterology. 2017 Jan;152(1):300-301. doi: 10.1053/j.gastro.2016.05.060. Epub 2016 Nov 21.

UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jan 15;1073:183-190. doi: 10.1016/j.jchromb.2017.12.018. Epub 2017 Dec 12.

Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.

Aliment Pharmacol Ther. 2016 Jun;43(12):1319-29. doi: 10.1111/apt.13629. Epub 2016 Apr 21.

Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.

AIDS. 2016 Jan 2;30(1):93-8. doi: 10.1097/QAD.0000000000000887.

Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.

Int J Infect Dis. 2016 Aug;49:151-3. doi: 10.1016/j.ijid.2016.06.020. Epub 2016 Jul 1.

Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.

Clin Ther. 2016 Feb;38(2):404-12. doi: 10.1016/j.clinthera.2015.12.017. Epub 2016 Feb 3.

Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in an HIV-HCV-coinfected patient.

Antivir Ther. 2015;20(3):353-6. doi: 10.3851/IMP2841. Epub 2014 Aug 8.

A Closing Chapter: Hepatitis C Genotype 3 Elimination in Liver Transplant; Sofosbuvir/Daclatasvir in a Hard-to-Treat Population.

Exp Clin Transplant. 2018 Feb;16(1):61-67. doi: 10.6002/ect.2016.0296. Epub 2017 Nov 15.

Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.

BMC Infect Dis. 2017 Mar 1;17(1):182. doi: 10.1186/s12879-017-2287-y.

Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation: Results From the ANRS CO23 CUPILT Study.

Transplantation. 2018 Jan;102(1):119-126. doi: 10.1097/TP.0000000000001928.

引用本文的文献

Viral hepatitis E: Clinical manifestations, treatment, and prevention.

Liver Res. 2024 Jan 6;8(1):11-21. doi: 10.1016/j.livres.2024.01.001. eCollection 2024 Mar.

Dynamic evolution of the sofosbuvir-associated variant A1343V in HEV-infected patients under concomitant sofosbuvir-ribavirin treatment.

JHEP Rep. 2024 Jan 3;6(3):100989. doi: 10.1016/j.jhepr.2023.100989. eCollection 2024 Mar.

Hepatitis E infection: A review.

World J Virol. 2023 Dec 25;12(5):262-271. doi: 10.5501/wjv.v12.i5.262.

Treatment of Hepatitis E.

Adv Exp Med Biol. 2023;1417:215-226. doi: 10.1007/978-981-99-1304-6_15.

Repurposing of artesunate, an antimalarial drug, as a potential inhibitor of hepatitis E virus.

Arch Virol. 2023 Apr 28;168(5):147. doi: 10.1007/s00705-023-05770-1.

Sofosbuvir in the Treatment of Hepatitis E virus Infection: A Review of and Evidence.

J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1225-1237. doi: 10.1016/j.jceh.2022.02.003. Epub 2022 Feb 22.

World J Gastroenterol. 2022 Mar 28;28(12):1226-1238. doi: 10.3748/wjg.v28.i12.1226.

Viral Interference of Hepatitis C and E Virus Replication in Novel Experimental Co-Infection Systems.

Cells. 2022 Mar 8;11(6):927. doi: 10.3390/cells11060927.

Viral hepatitis in 2021: The challenges remaining and how we should tackle them.

World J Gastroenterol. 2022 Jan 7;28(1):76-95. doi: 10.3748/wjg.v28.i1.76.

Treatment for chronic hepatitis E virus infection: A systematic review and meta-analysis.

J Viral Hepat. 2021 Mar;28(3):454-463. doi: 10.1111/jvh.13456. Epub 2020 Dec 20.

Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient.

作者信息

机构信息

出版信息

相似文献

引用本文的文献